UBS/CALL/ELI LILLY & CO/900.001/0.01/20.09.24 | Market Closed - Swiss Exchange 11:15:01 2024-05-23 am EDT | ||
| 0.27 CHF | +3.85% |
|
| Current month | +22.73% | ||
| 1 month | +50.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.27 | +3.85% |
| 24-05-21 | 0.26 | +44.44% |
| 24-05-17 | 0.18 | -5.26% |
| 24-05-15 | 0.19 | +26.67% |
Delayed Quote Swiss Exchange
Last update May 23, 2024 at 11:15 am EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYEOU | |
| ISIN | CH1299193321 |
| Date issued | 2023-10-16 |
| Strike | 900 $ |
| Maturity | 2024-09-20 (120 Days) |
| Parity | 100 : 1 |
| Emission price | 0.11 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.41 CHF |
|---|---|
| Lowest since issue | 0.06 CHF |
| Spread | 0.01 CHF |
| Spread % | 3.45% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.96%
- Stock Market
- Warrants
- LLYEOU Warrant
